Evidence map›Paper›PMID 29438462›Full record

ReviewAdvances in nutrition (Bethesda, Md.)2018

Butyrate: A Double-Edged Sword for Health?

Hu Liu, Ji Wang, Ting He, Sage Becker, Guolong Zhang, Defa Li, Xi Ma

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Advances in nutrition (Bethesda, Md.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05119010 (A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma), which is not on this map. Cited by 626 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
626citing papers in PubMed, 4 pooled it
49.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05119010 naterminatednot on this mapstarted 2023, after this paper: background citation

A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

TypeinterventionalSponsorGustave Roussy, Cancer Campus, Grand ParisRan2023 to 2024Enrolled3ConditionsMetastatic Renal Cell CarcinomaArmsContinuous ketogenic diet, Discontinuous ketogenic diet, beta-hydroxybutyrate (BHB) supplementation
3 · Its place in the literature

Who cites it

626 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,091 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Effect ofNutrients · 2026
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Bridging the gap:Gut microbes · 2026
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

566 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Hu LiuState Key Laboratory of Animal Nutrition, China Agricultural University, Beijing, China.
Ji WangState Key Laboratory of Animal Nutrition, China Agricultural University, Beijing, China.
Ting HeState Key Laboratory of Animal Nutrition, China Agricultural University, Beijing, China.
Sage BeckerDepartment of Animal Science, Oklahoma State University, Stillwater, OK; Departments of Internal Medicine and Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX.
Guolong ZhangDepartment of Animal Science, Oklahoma State University, Stillwater, OK; Departments of Internal Medicine and Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX.
Defa LiState Key Laboratory of Animal Nutrition, China Agricultural University, Beijing, China.
Xi MaState Key Laboratory of Animal Nutrition, China Agricultural University, Beijing, China.
China Agricultural University · CNOklahoma State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Butyrate, a four-carbon short-chain fatty acid, is produced through microbial fermentation of dietary fibers in the lower intestinal tract. Endogenous butyrate production, delivery, and absorption by colonocytes have been well documented. Butyrate exerts its functions by acting as a histone deacetylase (HDAC) inhibitor or signaling through several G protein-coupled receptors (GPCRs). Recently, butyrate has received particular attention for its beneficial effects on intestinal homeostasis and energy metabolism. With anti-inflammatory properties, butyrate enhances intestinal barrier function and mucosal immunity. However, the role of butyrate in obesity remains controversial. Growing evidence has highlighted the impact of butyrate on the gut-brain axis. In this review, we summarize the present knowledge on the properties of butyrate, especially its potential effects and mechanisms involved in intestinal health and obesity.

Indexed as

ObesityAnti-Inflammatory AgentsButyratesColonDietary FiberEnergy MetabolismFermentationGastrointestinal MicrobiomeGlycolipidsHistone Deacetylase InhibitorsHumansIntestinal AbsorptionIntestinal MucosaReceptors, G-Protein-CoupledSignal TransductionAnti-Inflammatory AgentsButyratesDietary FiberGlycolipidsHistone Deacetylase InhibitorsReceptors, G-Protein-CoupledbutyrateG protein–coupled receptorsgut-brain axishistone deacetylaseinflammationintestinal barrierintestinal microbiotaobesity

Identifiers

PMID29438462
PMCPMC6333934
OpenAlexW2793072766

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.